PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9544377

Persistent müllerian duct syndrome.

D E Rizk·M Ezimokhai·A S Hussein·S Gerami·P Deb
View original source ↗Export metadata ↓

Abstract

We report an 18-month old male presenting with a right-sided inguinal hernia and undescended testes. At herniotomy, a uterus and two fallopian tubes were found in the pelvic peritoneum adjacent to the two gonads which received their blood supply partly along the müllerian duct remnants. The gonads were testes by histological examination. Bilateral orchiopexy was performed without removal of the müllerian structures for fear of jeopardizing the testicular blood supply. The diagnosis of persistent müllerian duct syndrome was confirmed postoperatively by genetic and hormonal investigations.

Explore related subjects

Anti-Mullerian HormoneCryptorchidismDisorders of Sex DevelopmentFallopian TubesFemaleGlycoproteinsGrowth InhibitorsHernia, InguinalHumansInfantMaleMullerian DuctsOmanSyndromeTesticular HormonesUterusCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D E Rizk, M Ezimokhai, A S Hussein, S Gerami, P Deb. 1998. Persistent müllerian duct syndrome.. https://doi.org/10.1007/s004040050208

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

The Anti-Mullerian hormone and ovarian cancer.

The Anti-Mullerian hormone (AMH), which is produced by fetal Sertoli cells, is responsible for regression of Mullerian ducts, the anlagen for uterus and Fallopian tubes, during male sex differentiation. Ovarian granulosa cells also secrete AMH from late in fetal life. The patterns of expression of AMH and its type II receptor in the post-natal ovary indicate that AMH may play an important role in ovarian folliculogenesis. Recent advances in the physiological role of AMH has stimulated interest in the significance of AMH as a diagnostic marker and therapeutic agent for ovarian cancer. Currently, AMH has been shown to be a circulating marker specifically for granulosa cell tumour (GCT). Its diagnostic performance seems to be very good, with a sensitivity ranging between 76 and 93%. In patients treated for GCT, AMH may be used post-operatively as marker for the efficacy of surgery and for disease recurrence. Based on the physiological inhibitory role of AMH in the Mullerian ducts, it has been proposed that AMH may inhibit epithelial ovarian cancer cell both in vitro and in vivo. These observations will be the basis for future research aiming to investigate the possible clinical role of AMH as neo-adjuvant, or most probably adjuvant, therapy for ovarian cancer.

Anti-Mullerian Hormone↗
PubMed2006

Antimüllerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate.

The size of the pool of growing follicles was normal after prolonged down-regulation, as indicated by normal AMH levels 4 and 8 weeks after goserelin administration. However, there was a profound down-regulation of LH levels; therefore we suggest administration of exogenous LH to proceed to IVF or alternatively stimulation of endogenous LH secretion with daily administration of GnRH agonist. These need to be assessed prospectively.

Anti-Mullerian Hormone↗